Ftse Mib
34.249,77
0,91%
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
NASDAQ Composite
15.927,90
2,03%
Bitcoin
63.081,73
-1,03%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistenza
Home Investire Azioni Regno Unito LSE Okyo Pharma Limited (OKYO) Okyo Pharma Limited (OKYO) Notizie

Okyo Pharma Limited

OKYO
91,00
0,00 (0,00%)
26 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: Londra
Tipo: Azione Ordinaria
Valuta: GBX

Ultime notizie

Data Ora Fonte Titolo
09/4/202401:00UKREGOKYO Pharma to Reschedule Key Opinion Leader Event in Dry..
02/4/202413:00UKREGOKYO Pharma Announces Upcoming Presentation of OK-101 Phase..
22/3/202412:00UKREGOKYO Pharma Announces OK-101 Successfully Achieved..
21/3/202412:00UKREGOKYO Pharma to Host Key Opinion Leader Event to Discuss New..
20/3/202412:00UKREGOKYO Pharma to Release New and Comprehensive Data from Phase..
09/2/202413:36IHNWOKYO Pharma Receives FDA Approval of IND for OK-101 in..
09/2/202413:00UKREGOKYO Pharma Receives FDA Approval of IND for OK-101 in..
31/1/202413:00UKREGOKYO Pharma Announces Distinguished Ophthalmologists with..
08/1/202413:00GLOBEOKYO Pharma Announces OK-101 Successfully Achieved..
05/1/202415:30GLOBEOKYO Pharma to Present at the Biotech Showcase Conference in..
04/12/202313:00GLOBEOKYO Pharma Announces Last Patient Enrolled in OK-101 Phase..
31/10/202312:00GLOBEOKYO Pharma Announces $5.84 Million Cash Raise and Payables..
09/10/202313:00GLOBEOKYO Pharma Announces Filing of an Investigational New Drug..
05/10/202313:00GLOBEOKYO Pharma Announces Positive Safety Data Profile for the..
15/9/202313:00GLOBEOKYO Pharma Announces Closing of $4.0 Million Registered..
14/9/202315:15GLOBEOKYO Pharma Announces Pricing of $4.0 Million Registered..
14/9/202314:45GLOBEOKYO Pharma Limited Announces Withdrawal of Public Offering
13/9/202322:05GLOBEOKYO Pharma Announces Public Offering of Ordinary Shares
08/9/202313:00GLOBEOKYO Pharma Completes Enrollment in Phase 2 Clinical Trial..
30/8/202313:00GLOBEOKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2..
29/8/202313:00GLOBEOKYO Pharma Limited Regains Compliance with Nasdaq Listing..
15/8/202315:00GLOBEOKYO Pharma Limited Reports Annual Results for the Twelve..
31/7/202308:18GLOBEOKYO Pharma Limited Announces Withdrawal of Public Offering
28/7/202323:25GLOBEOKYO Pharma Announces Proposed Public Offering of Ordinary..
28/7/202323:05GLOBEOKYO Pharma Limited Receives Nasdaq Deficiency Notice
28/7/202313:01GLOBEOKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in..
27/7/202317:30GLOBEOKYO Pharma Announces Appointment of William A. Clementi as..
06/6/202315:30GLOBEOKYO Pharma Announces Randomized Segment Now Underway in..
22/5/202309:15UKREGOKYO Pharma Limited London Stock Exchange Delisting
22/5/202309:00UKREGLondon Stock Exchange Notice Cancellation - OKYO PHARMA..
19/5/202312:22ALNCNewsIN BRIEF: Okyo Pharma to move shares to New York with London..
19/5/202309:00RNSNONOKYO Pharma Limited ADS Program collapse
15/5/202308:00UKREGOKYO Pharma Limited Change of Record Time and Last Day of..
11/5/202315:27ALNCNewsIN BRIEF: Okyo Pharma delays delisting from London trading..
11/5/202313:00RNSNONOKYO Pharma Limited Webull Corporate Communications Service..
11/5/202308:00UKREGOKYO Pharma Limited Change of Delisting Date to 22 May 2023
03/5/202314:00UKREGOKYO Pharma Limited Result of Meeting
03/5/202308:00GLOBEOKYO Pharma Announces Presentations at the American Society..
02/5/202321:16ALNCNewsTRADING UPDATES: Knights Group buys St James Law and Baines..
02/5/202308:00GLOBEOKYO Pharma Announces First-Patient First-Visit for Phase 2..
02/5/202308:00UKREGOKYO Pharma Limited First-Patient First-Visit for Phase 2..
Apertura: Min: Max:
Chiusura: 91,00

La tua Cronologia

LSE
OKYO
Okyo Pharma
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network